Global Hematologic Malignancies Testing Market

Focus on Hematologic Malignancies Testing Product and Application, Supply Chain Analysis, and Country Analysis - Analysis and Forecast, 2022-2032

Published Year:
SKU:BHP0771SB

$5250

Online Access for 1-3 Users. Permission to Print.


In case you require a hard copy, there will be an additional charge of $500. Please email us at [email protected] with your request.

A quick peek into the report

Market Report Coverage

Hematologic Malignancies Testing Market
Forecast Period: 2022-2032
CAGR During Forecast Period: 14.23%

Global Hematologic Malignancies Testing Market

Base Year

2021

Market Size in 2021

$2,606.5 Million

Forecast Period

2022-2032

Value Projection and Estimation by 2032

$11,680.1 Million

CAGR During Forecast Period

14.23%

Number of Tables

19

Number of Pages

278

Number of Figures

276

 

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

•    Abbott.
•    ASURAGEN, INC.
•    Adaptive Biotechnologies
•    ARUP Laboratories
•    Bio-Rad Laboratories, Inc.
•    F. Hoffmann-La Roche Ltd
•    Illumina, Inc.
•    ICON plc
•    Invivoscribe, Inc.
•    Invitae Corporation.
•    Laboratory Corporation of America Holdings
•    NeoGenomics Laboratories
•    OHSU’s Knight Diagnostic Laboratories
•    Precipio
•    QIAGEN N.V.
•    Quest Diagnostics
•    Sysmex Corporation

How Can This Report Add Value to an Organization?

The study provides the reader with a detailed understanding of the different diseases such as leukemia, lymphoma, multiple myeloma

Product/Innovation Strategy: The product segment helps the reader understand the types of products, i.e., kits and services. These ecosystems are the primary focus of the study as these are the target of market players in terms of revenue generation. Moreover, the study provides the reader with a detailed understanding of the different diseases such as leukemia, lymphoma, multiple myeloma, myeloproliferative neoplasm, and myelodysplastic syndrome.

Growth/Marketing Strategy: The hematologic malignancies testing market has been dominated significantly by companies such as QIAGEN N.V., Abbott., Bio-Rad Laboratories, Inc., and F. Hoffmann-La Roche Ltd due to their expansive portfolio and strong regional presence across the world. Many companies such as Precipio, Sysmex Corporation, Illumina, Inc., ARUP Laboratories, and Adaptive Biotechnologies lie in the low growth and low market share segment. The low market share of these companies is primarily due to limited products with respect to the hematologic malignancies testing market in comparison to other segments of these companies. Also, the lack of synergistic activities with respect to the market is responsible for the low growth of these companies.

Competitive Strategy: Key players in the hematologic malignancies testing market analyzed and profiled in the study has involved the oncology application-based product manufacturers that provide hematologic malignancies testing kits and services. Moreover, a detailed competitive benchmarking of the players operating in the hematologic malignancies testing market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Industry & Technology Overview

The market is projected to reach $11,680.1 million by 2032, growing from $2,606.5 million in 2021.

Hematologic Malignancies Testing Market: Industry Overview

The global hematologic malignancies testing market is projected to reach $11,680.1 million by 2032, growing from $2,606.5 million in 2021, at a CAGR of 14.23% during the forecast period 2022-2032. The global market for hematologic malignancies testing has grown significantly, owing to the rising demand for numerous biomarker-based molecular diagnostics. The advancements have aided in enhancing the quality of life and decreasing treatment costs and time, driving the overall growth of the healthcare diagnostics market. Furthermore, the worldwide hematologic malignancies testing market is being driven by rising awareness and adoption of the precision diagnostic technique in both developed and developing countries.

Market Lifecycle Stage

Hematologic malignancies are a type of cancer that starts in blood-forming tissue, such as the bone marrow or immune system cells. With an enhanced genomic review of cancer and developments in molecular diagnostic technology, genetic characterization has become increasingly important in the clinical evaluation of practically every kind of hematologic malignancy. In economically developed countries, hematological malignancies (blood cancers) are the fifth most prevalent cancer kind. They're generally divided into three groups based on whether cancer starts in the blood (leukemia), lymph nodes (Hodgkin’s lymphoma and non-Hodgkin’s lymphoma), or bone (osteosarcomas and myelomas). The global hematologic malignancies testing market is undergoing a significant change about the advancements that have already taken place and are currently invading the market space. Additionally, with the emergence of advanced diagnostic technologies, there is immense potential for emerging submarkets such as the nucleic acid extraction market to continue fueling the overall hematologic malignancies testing market. Further, with highly opportunistic trends coming into play with the rapid incorporation of hematologic malignancies testing in the management of cancer in healthcare settings, there is immense potential for growth in this market.

Figure: Hematologic Malignancies Testing Market Snapshot

Global Hematologic Malignancies Testing Market

Source: BIS Research Analysis

Impact

•   The presence of major service providers of hematologic malignancies testing products has a significant impact on the market. For instance, In South Bend, Indiana, Laboratory Corporation of America Holdings opened a new diagnostics laboratory, allowing the company to expand service levels and products to patients and doctors in the area.
•   Companies such as F. Hoffmann-La Roche Ltd released the AVENIO Tumor Tissue CGP Kit, which complements Roche and Foundation Medicine's current CGP offering and enables laboratories to extend their oncology research in-house. In the end, a future version of the kit could result in more resources for clinicians to employ in cancer diagnosis and therapy. The presence of such products has a positive impact on market growth.

Impact of COVID-19

In the U.S. and around the world, cancer is the leading cause of death. Cancer testing is an important preventive measure that can lower the incidence and death of cancer. While cancer prevention and screening are important for individual and societal health, the cancer market is undergoing significant changes because of the COVID-19 epidemic. COVID-19-related disruptions have impacted nearly every area of cancer control and prevention infrastructure, which includes canceled cancer diagnostic tests, postponed elective surgeries, deconstructed therapy regimens, and unemployed healthcare providers. Patients, healthcare providers, and healthcare systems may all suffer because of the disruption in cancer screening tests.

Cancer screening is crucial for early cancer detection; however, COVID-19 has slowed the cancer screening infrastructure greatly. Many cancer organizations have championed the idea of suspending cancer screening services to patients to alter the provision of healthcare resources. Following the declaration of a national emergency in the U.S. on March 13, 2020, organizations such as the American Cancer Society advised people to put their cancer screening plans on hold until further notice during the COVID-19 outbreak. Cancer screening services have been severely disrupted because of this proposal, as well as other contextual circumstances (e.g., social exclusion measures).

Successful cancer screening is frequently achieved through synergistic collaborations among patients, healthcare providers, and health systems. Furthermore, because there is no information on the virus' origins and no effective vaccination or curative therapy, both patients and healthcare providers share the same unknowns and doubts about COVID-19. Health systems, whose financial prospects may be challenged, are also affected by this uncertainty. It is expected that, with the restrictions gradually being removed from several regions around the world, coupled with research activities resuming normalcy, the market will face a low impact on the annual revenue generation.

Market Segmentation

Segmentation 1: by Platform
•    Polymerase Chain Reaction (PCR)
•    Next-Generation Sequencing (NGS)
•    Fluorescence In-Situ Hybridization (FISH)
•    Flow Cytometry
•    Immunohistochemistry (IHC)
•    Other Platforms

The hematologic malignancies testing market (by platform) was dominated by the polymerase chain reaction (PCR) segment in 2021. This was due to an increasing number of PCR kits that providers offer to their end users.

Segmentation 2: by Disease
•    Leukemia
•    Lymphoma
•    Multiple Myeloma
•    Myeloproliferative Neoplasm
•    Myelodysplastic Syndrome

In 2021, leukemia disease dominated the hematologic malignancies testing market due to an increasing number of patients suffering from cancer. According to the data published by the World Health Organization, cancer is a leading cause of death, with nearly 10 million deaths reported in 2020.

Segmentation 3: by Product
•    Kits
•    Services

The hematologic malignancies testing market (by product) was dominated by the services segment in 2021. This growth was attributed to academic research and industry collaboration. Moreover, the technological advancement in RUO products is boosting the growth of the hematologic malignancies testing market.

Segmentation 4: by End User
•    Specialty Clinics and Hospitals
•    Diagnostic Laboratories 
•    Reference Laboratories
•    Research Institutions

In 2021, the hematologic malignancies testing market (by end user) was dominated by the specialty clinics, and hospitals segment as these clinics have all the necessary information and topic competence to perform disease diagnostic tests.

Segmentation 5: by Region
•    North America
•    Europe
•    Asia-Pacific
•    Latin America
•    Rest-of-the-World

North America generated the highest revenue of $1,491.7 million in 2021, which is attributed to the R&D advancements in the field of oncology testing and the presence of dominating players operating in the hematologic malignancies testing market.

Recent Developments in Hematologic Malignancies Testing Market

•    In August 2021, GRAIL, a healthcare business focused on life-saving early identification of various malignancies, was acquired by Illumina, Inc. The Galleri blood test developed by GRAIL diagnoses various malignancies before they become symptomatic. GRAIL's acquisition by Illumina has accelerated access to and acceptance of the life-saving test around the world.
•    In October 2021, F. Hoffmann-La Roche Ltd released the AVENIO Tumor Tissue CGP Kit, enabling laboratories to extend their oncology research in-house.
•    In January 2021, F. Hoffmann-La Roche Ltd partnered with Sysmex Corporation to evolve and provide hematology testing advances to laboratories around the world. The firms have renewed their long-standing distribution, sales, and services (DSS) agreement, allowing Roche to continue to distribute Sysmex hematology goods, including instruments and reagents.

Demand – Drivers and Limitations

Following are the demand drivers for the hematologic malignancies testing market:

•    Increasing Key Player Initiatives
•    Growing Funding in the Market for Hematologic Malignancies Testing

The market is expected to face some limitations too due to the following challenges:

•    Lack of Qualified Professionals
•    Issues Concerning the Analytical Validity of Cancer Genetic Testing

Analyst Thoughts

According to Nitish Kumar, Principal Analyst, BIS Research, "The hematologic malignancies testing market is an emerging segment comprising the overall diagnostics ecosystem. Moreover, the increasing prevalence of cancer and technological advancement in the field of cancer diagnostic are the significant factors driving the growth of the hematologic malignancies testing market."

Table of Contents

Download this TOC

Get Free Sample

1.1    Product Definition
         1.1.1    Inclusion and Exclusion
1.2    Market Scope
         1.2.1    Scope of the Study
         1.2.2    Key Questions Answered in the Report
1.3    Market Overview
         1.3.1    Introduction
         1.3.2    Types of Hematologic Malignancies Diagnostic Tests
         1.3.3    Market Footprint and Growth Potential

2.1    Overview
2.2    Impact Analysis
2.3    Market Drivers
         2.3.1    Rising Incidence in Hematologic Malignancies
                     2.3.1.1    New Cases
                     2.3.1.2    Deaths
         2.3.2    Increasing Key Player Initiatives
         2.3.3    Growing Funding in the Market for Hematologic Malignancies Testing
2.4    Market Restraints
         2.4.1    Lack of Qualified Professionals
         2.4.2    Issues Concerning the Analytical Validity of Cancer Genetic Testing
2.5    Market Opportunities
         2.5.1    Increasing Research and Development Activities
         2.5.2    Technological Advancements in the Field of Hematologic Malignancies Testing
2.6    Industry Analysis
         2.6.1    Regulatory Framework
         2.6.2    Regulatory Framework in the U.S.
         2.6.3    Regulatory Framework in Europe
         2.6.4    Regulatory Framework in Asia-Pacific
                     2.6.4.1    Japan
                     2.6.4.2    China
2.7    COVID-19's Impact on Cancer Diagnostic Market
         2.7.1    Disruption in Global Hematologic Malignancies Testing Market Due to COVID-19
         2.7.2    Effect of COVID-19 on Cancer Medicine and Science
         2.7.3    Effect on Workforce and Research Funding
         2.7.4    Effect on Cancer Screening
         2.7.5    Future of Cancer Beyond COVID-19 in Medicine and Science
                     2.7.5.1    Implementation of Telemedicine
2.8    Supply Chain Analysis
         2.8.1    Key Entities in Supply Chain
2.9    Pricing Analysis
         2.9.1    Pricing Analysis By Platform Testing
2.10    Comparative Analysis of Hematologic Malignancies Test by Different Parameters

3.1    Overview
3.2    Synergistic Activities
3.3    Product Launches
3.4    Product Approvals
3.5    Mergers and Acquisitions
3.6    Other Business Activities
3.7    Market Share Analysis (by Company), 2020 and 2021
3.8    Growth-Share Analysis (by Platform)

4.1    Overview
         4.1.1    Kits
                     4.1.1.1    Gene Panels
                     4.1.1.2    Molecular Clonality Testing
                     4.1.1.3    Translocation Testing
                     4.1.1.4    Mutation Testing
                     4.1.1.5    Minimal Residual Disease (MRD) Testing
         4.1.2    Services

5.1    Overview
         5.1.1    Next-Generation Sequencing (NGS)
         5.1.2    Polymerase Chain Reaction (PCR)
         5.1.3    Fluorescence In-Situ Hybridization (FISH)
         5.1.4    Immunohistochemistry (IHC)
         5.1.5    Flow Cytometry
         5.1.6    Other Platforms
                     5.1.6.1    Cytogenetic Testing
                     5.1.6.2    Microarray

6.1    Overview
6.2    Leukemia
6.3    Lymphoma
6.4    Multiple Myeloma
6.5    Myeloproliferative Neoplasms
6.6    Myelodysplastic Syndromes

7.1    Overview
7.2    Specialty Clinics and Hospitals
7.3    Diagnostic Laboratories
7.4    Reference Laboratories
7.5    Research Institutions

8.1    Overview
8.2    North America
         8.2.1    U.S.
         8.2.2    Canada
8.3    Europe
         8.3.1    Germany
         8.3.2    France
         8.3.3    U.K.
         8.3.4    Italy
         8.3.5    Spain
         8.3.6    Denmark
         8.3.7    Rest-of-Europe
8.4    Asia-Pacific
         8.4.1    China
         8.4.2    Japan
         8.4.3    India
         8.4.4    South Korea
         8.4.5    Australia
         8.4.6    Singapore
         8.4.7    Rest-of-Asia-Pacific
8.5    Latin America
         8.5.1    Brazil
         8.5.2    Mexico
         8.5.3    Rest-of-Latin America
8.6    Rest-of-the-World

9.1    Overview
9.2    Abbott.
         9.2.1    Company Overview
         9.2.2    Role of Abbott. in the Global Hematologic Malignancies Testing Market
         9.2.3    Key Competitors of the Company
         9.2.4    Key Customers of the Company
         9.2.5    Corporate Strategies
         9.2.6    Financials
         9.2.7    Key Insights about the Financial Health of the Company
         9.2.8    Analyst Perspectives
9.3    ASURAGEN, INC.
         9.3.1    Company Overview
         9.3.2    Role of ASURAGEN, INC. in the Global Hematologic Malignancies Testing Market
         9.3.3    Key Competitors of the Company
         9.3.4    Key Customers of the Company
         9.3.5    Analyst Perspectives
9.4    Adaptive Biotechnologies
         9.4.1    Company Overview
         9.4.2    Role of Adaptive Biotechnologies in the Global Hematologic Malignancies Testing Market
         9.4.3    Key Competitors of the Company
         9.4.4    Key Customers of the Company
         9.4.5    Corporate Strategies
         9.4.6    Financials
         9.4.7    Key Insights about the Financial Health of the Company
         9.4.8    Analyst Perspectives
9.5    ARUP Laboratories
         9.5.1    Company Overview
         9.5.2    Role of ARUP Laboratories in the Global Hematologic Malignancies Testing Market
         9.5.3    Key Competitors of the Company
         9.5.4    Key Customers of the Company
         9.5.5    Analyst Perspectives
9.6    Bio-Rad Laboratories, Inc.
         9.6.1    Company Overview
         9.6.2    Role of Bio-Rad Laboratories, Inc. in the Global Hematologic Malignancies Testing Market
         9.6.3    Key Competitors of the Company
         9.6.4    Key Customers of the Company
         9.6.5    Financials
         9.6.6    Key Insights about the Financial Health of the Company
         9.6.7    Analyst Perspectives
9.7    F. Hoffmann-La Roche Ltd
         9.7.1    Company Overview
         9.7.2    Role of F. Hoffmann-La Roche Ltd in the Global Hematologic Malignancies Testing Market
         9.7.3    Key Competitors of the Company
         9.7.4    Key Customers of the Company
         9.7.5    Corporate Strategies
         9.7.6    Business Strategies
         9.7.7    Financials
         9.7.8    Key Insights about the Financial Health of the Company
         9.7.9    Analyst Perspectives
9.8    Illumina, Inc.
         9.8.1    Company Overview
         9.8.2    Role of Illumina, Inc. in the Global Hematology Malignancies Testing Market
         9.8.3    Key Competitors of the Company
         9.8.4    Key Customers of the Company
         9.8.5    Corporate Strategies
         9.8.6    Financials
         9.8.7    Key Insights about the Financial Health of the Company
         9.8.8    Analyst Perspectives
9.9    ICON plc
         9.9.1    Company Overview
         9.9.2    Role of ICON plc in the Global Hematologic Malignancies Testing Market
         9.9.3    Key Competitors of the Company
         9.9.4    Key Customers of the Company
         9.9.5    Financials
         9.9.6    Analyst Perspectives
9.10    Invivoscribe, Inc.
           9.10.1    Company Overview
           9.10.2    Role of Invivoscribe, Inc. in the Global Hematologic Malignancies Testing Market
           9.10.3    Key Competitors of the Company
           9.10.4    Key Customers of the Company
           9.10.5    Analyst Perspectives
9.11    Invitae Corporation.
           9.11.1    Company Overview
           9.11.2    Role of Invitae Corporation. in the Global Hematologic Malignancies Testing Market
           9.11.3    Key Competitors of the Company
           9.11.4    Key Customers of the Company
           9.11.5    Corporate Strategies
           9.11.6    Financials
           9.11.7    Key Insights about the Financial Health of the Company
           9.11.8    Analyst Perspectives
9.12    Laboratory Corporation of America Holdings
           9.12.1    Company Overview
           9.12.2    Role of Laboratory Corporation of America Holdings in the Global Hematologic Malignancies Testing Market
           9.12.3    Key Competitors of the Company
           9.12.4    Key Customers of the Company
           9.12.5    Corporate Strategies
           9.12.6    Financials
           9.12.7    Analyst Perspectives
9.13    NeoGenomics Laboratories
           9.13.1    Company Overview
           9.13.2    Role of NeoGenomics Laboratories in the Global Hematologic Malignancies Testing Market
           9.13.3    Key Competitors of the Company
           9.13.4    Key Customers of the Company
           9.13.5    Financials
           9.13.6    Key Insights about the Financial Health of the Company
           9.13.7    Analyst Perspectives
9.14    OHSU’s Knight Diagnostic Laboratories
           9.14.1    Company Overview
           9.14.2    Role of OHSU’s Knight Diagnostic Laboratories in the Global Hematologic Malignancies Testing Market
           9.14.3    Key Competitors of the Company
           9.14.4    Key Customers of the Company
           9.14.5    Analyst Perspectives
9.15    Precipio
           9.15.1    Company Overview
           9.15.2    Role of Precipio in the Global Hematologic Malignancies Testing Market
           9.15.3    Key Competitors of the Company
           9.15.4    Key Customers of the Company
           9.15.5    Corporate Strategies
           9.15.6    Business Strategies
           9.15.7    Financials
           9.15.8    Analyst Perspectives
9.16    QIAGEN N.V.
           9.16.1    Company Overview
           9.16.2    Role of QIAGEN N.V. in the Global Hematologic Malignancies Testing Market
           9.16.3    Key Competitors of the Company
           9.16.4    Key Customers of the Company
           9.16.5    Corporate Strategies
           9.16.6    Financials
           9.16.7    Key Insights about the Financial Health of the Company
           9.16.8    Analyst Perspectives
9.17    Quest Diagnostics
           9.17.1    Company Overview
           9.17.2    Role of Quest Diagnostics in the Global Hematologic Malignancies Testing Market
           9.17.3    Key Competitors of the Company
           9.17.4    Key Customers of the Company
           9.17.5    Corporate Strategies
           9.17.6    Financials
           9.17.7    Analyst Perspectives
9.18    Sysmex Corporation
           9.18.1    Company Overview
           9.18.2    Role of Sysmex Corporation in the Global Hematologic Malignancies Testing Market
           9.18.3    Key Competitors of the Company
           9.18.4    Key Customers of the Company
           9.18.5    Business Strategies
           9.18.6    Financials
           9.18.7    Key Insights about the Financial Health of the Company
           9.18.8    Analyst Perspectives

Table 1:    Diagnostic Tests for Hematologic Malignancies
Table 2:    Likert Scale
Table 3:    Impact Analysis of Market Drivers
Table 4:    Impact Analysis of Market Restraints
Table 5:    Registration Criteria for IVDs as per the CFDA
Table 6:    Effect of COVID-19 on Cancer Care Throughout the World
Table 7:    Companies Offering Gene Panels
Table 8:    Companies Offering Services
Table 9:    NGS-Based Products
Table 10:    PCR-Based Products
Table 11:    Companies Offering FISH-Based Products
Table 12:    Companies Offering IHC-Based Products
Table 13:    Company Offering Flow Cytometry-Based Product
Table 14:    Estimated Cases of Leukemia, by Gender, 2021
Table 15:    Companies Offering Leukemia Testing Products
Table 16:    Estimated Cases of Lymphoma, by Gender, 2021
Table 17:    Companies Offering Lymphoma Testing Products
Table 18:    Estimated Cases of Myeloma, by Gender, 2021
Table 19:    Companies Offering Multiple Myeloma Products

Figure 1:    Estimated Hematologic Malignancies Cases
Figure 2:    Impact Analysis of Market Drivers and Market Challenges on the Global Hematologic Malignancies Testing Market
Figure 3:    Global Hematologic Malignancies Testing Market (by Product), $Million, 2021 and 2032
Figure 4:    Global Hematologic Malignancies Testing Market (by Platform), $Million, 2021 and 2032
Figure 5:    Global Hematologic Malignancies Testing Market (by Disease), $Million, 2021 and 2032
Figure 6:    Global Hematologic Malignancies Testing Market (by End User), $Million, 2021 and 2032
Figure 7:    Global Hematologic Malignancies Testing Market
Figure 8:    Global Hematologic Malignancies Testing Market: Research Methodology
Figure 9:    Primary Research Methodology
Figure 10:    Bottom-Up Approach (Segment-Wise Analysis)
Figure 11:    Global Hematologic Malignancies Testing Market Segmentation
Figure 12:    Classification of Hematologic Malignancies
Figure 13:    Global Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 14:    Blood Cancer Cases, 2021 (% Share)
Figure 15:    Workflow for the Product Approval in the Market
Figure 16:    Workflow for the IVD Product Approval
Figure 17:    Workflow for Medical Device Regulations
Figure 18:    Workflow for Market Approval of In-Vitro Diagnostics in China
Figure 19:    COVID-19 Poses Several Concerns for Patients, Health Care Providers, and Health Systems
Figure 20:    Global Hematologic Malignancies Testing Market: COVID-19 Impact Analysis
Figure 21:    Medical Research Cycle Interruption during the COVID-19 Pandemic
Figure 22:    Telemedicine's Potential Advantages
Figure 23:    Hematologic Malignancies Testing Supply Chain Analysis
Figure 24:    Share of Key Developments and Strategies, January 2018-May 2022
Figure 25:    Share of Synergistic Activities (by Company), January 2018-May 2022
Figure 26:    Number of Product Launches (by Company), January 2018-May 2022
Figure 27:    Share of Product Approval (by Company), January 2018-May 2022
Figure 28:    Share of Mergers and Acquisitions (by Company), January 2018-May 2022
Figure 29:    Share of other business activities (by Company), January 2018-May 2022
Figure 30:    Market Share Analysis of Global Hematologic Malignancies Testing Market (by Company), 2020 and 2021
Figure 31:    Growth-Share Analysis for Global Hematologic Malignancies Testing Market (by Platform), 2021
Figure 32:    Segmentation of Hematologic Malignancies Testing Market
Figure 33:    Share of Global Hematologic Malignancies Market (by Product), $Million, 2021 and 2032
Figure 34:    Global Hematologic Malignancies Testing Market (by Kits)
Figure 35:    Global Hematologic Malignancies Testing Market (Kits), $Million, 2021-2032
Figure 36:    Global Hematologic Malignancies Testing Market (Kits), Thousand Units, 2021-2032
Figure 37:    Global Hematologic Malignancies Testing Market (Gene Panels), $Million, 2021-2032
Figure 38:    Global Hematologic Malignancies Testing Market (Gene Panels), Thousand Units, 2021-2032
Figure 39:    Global Hematologic Malignancies Testing Market (Molecular Clonality Testing), $Million, 2021-2032
Figure 40:    Global Hematologic Malignancies Testing Market (Molecular Clonality Testing), Thousand Units, 2021-2032
Figure 41:    Company Offering Translocation Panel for Leukemia
Figure 42:    Global Hematologic Malignancies Testing Market (Translocation Testing), $Million, 2021-2032
Figure 43:    Global Hematologic Malignancies Testing Market (Translocation Testing), Thousand Units, 2021-2032
Figure 44:    Companies Offering Mutation Testing Kits
Figure 45:    Global Hematologic Malignancies Testing Market (Mutation Testing), $Million, 2021-2032
Figure 46:    Global Hematologic Malignancies Testing Market (Mutation testing), Thousand Units, 2021-2032
Figure 47:    Global Hematologic Malignancies Testing Market (Minimal Residual Disease (MRD) Testing), $Million, 2021-2032
Figure 48:    Global Hematologic Malignancies Testing Market (Minimal Residual Disease (MRD) Testing), Thousand Units, 2021-2032
Figure 49:    Global Hematologic Malignancies Testing Market (Services), $Million, 2021-2032
Figure 50:    Global Hematologic Malignancies Testing Market (Services), Thousand Units, 2021-2032
Figure 51:    Global Hematologic Malignancies Testing Market (by Platform)
Figure 52:    Share of Global Hematologic Malignancies Testing Market (by Platform), $Million, 2021 and 2032
Figure 53:    Benefits of NGS for Clinical Diagnostics and Biomarker Testing in Oncology
Figure 54:    Global Hematologic Malignancies Testing Market (Next-Generation Sequencing (NGS)), $Million, 2021-2032
Figure 55:    Global Hematologic Malignancies Testing Market (Next-Generation Sequencing), Thousand Units, 2021-2032
Figure 56:    Global Hematologic Malignancies Testing Market (Polymerase Chain Reaction (PCR)), $Million, 2021-2032
Figure 57:    Global Hematologic Malignancies Testing Market (Polymerase Chain Reaction (PCR)), Thousand Units, 2021-2032
Figure 58:    Global Hematologic Malignancies Testing Market (Fluorescence In-Situ Hybridization (FISH)), $Million, 2021-2032
Figure 59:    Global Hematologic Malignancies Testing Market (Fluorescence In-Situ Hybridization (FISH)), Thousand Units, 2021-2032
Figure 60:    Global Hematologic Malignancies Testing Market (Immunohistochemistry (IHC)), $Million, 2021-2032
Figure 61:    Global hematologic malignancies testing Market (Immunohistochemistry), Thousand Units, 2021-2032
Figure 62:    Global Hematologic Malignancies Testing Market (Flow Cytometry), $Million, 2021-2032
Figure 63:    Global Hematologic Malignancies Testing Market (Flow Cytometry), Thousand Units, 2021-2032
Figure 64:    Global Hematologic Malignancies Testing Market (Other Platforms), $Million, 2021-2032
Figure 65:    Global Hematologic Malignancies Testing Market (Other Platforms), Thousand Units, 2021-2032
Figure 66:    Share of Global Hematologic Malignancies Testing Market (by Disease), $Million, 2021 and 2032
Figure 67:    Global Hematologic Malignancies Testing Market (Leukemia), $Million, 2021-2032
Figure 68:    Global Hematologic Malignancies Testing Market (Lymphoma), $Million, 2021-2032
Figure 69:    Global Hematologic Malignancies Testing Market (Multiple Myeloma), $Million, 2021-2032
Figure 70:    Global Hematologic Malignancies Testing Market (Myeloproliferative Neoplasms), $Million, 2021-2032
Figure 71:    Global Hematologic Malignancies Testing Market (Myelodysplastic Syndromes), $Million, 2021-2032
Figure 72:    Share of Global Hematologic Malignancies Testing Market (by End User), $Million, 2021 and 2032
Figure 73:    Global Hematologic Malignancies Testing Market (Specialty Clinics and Hospitals), $Million, 2021-2032
Figure 74:    Global Hematologic Malignancies Testing Market (Specialty Clinics and Hospitals), Thousand Units, 2021-2032
Figure 75:    Global Hematologic Malignancies Testing Market (Diagnostic Laboratories), $Million, 2021-2032
Figure 76:    Global Hematologic Malignancies Testing Market (Diagnostic Laboratories), Thousand Units, 2021-2032
Figure 77:    Global Hematologic Malignancies Testing Market (Reference Laboratories), $Million, 2021-2032
Figure 78:    Global Hematologic Malignancies Testing Market (Reference Laboratories), Thousand Units, 2021-2032
Figure 79:    Global Hematologic Malignancies Testing Market (Research Institutions), $Million, 2021-2032
Figure 80:    Global Hematologic Malignancies Testing Market (Research Institutions), Thousand Units, 2021-2032
Figure 81:    Global Hematologic Malignancies Testing Market Snapshot (by Region), $Million, 2021-2032
Figure 82:    Global Hematologic Malignancies Testing Market (by Region), $Million, 2021-2032
Figure 83:    North America Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 84:    North America: Market Dynamics
Figure 85:    North America Hematologic Malignancies Testing Market (by Country), $Million, 2021-2032
Figure 86:    North America Hematologic Malignancies Testing Market, Thousand Units, 2022-2032
Figure 87:    U.S. Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 88:    U.S. Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 89:    U.S. Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 90:    U.S. Hematologic Malignancies Testing Market (by Platform), Thousand Units, 2021, 2025, and 2032
Figure 91:    U.S. Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 92:    U.S. Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 93:    Canada Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 94:    Canada Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 95:    Canada Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 96:    Canada Hematologic Malignancies Testing Market (by Platform), Thousand Units, 2021, 2025, and 2032
Figure 97:    Canada Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 98:    Canada Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 99:    Europe Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 100:    Europe Hematologic Malignancies Testing Market (by Country), $Million, 2021-2032
Figure 101:    Europe: Market Dynamics
Figure 102:    Europe Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 103:    Germany Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 104:    Germany Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 105:    Germany Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 106:    Germany Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
Figure 107:    Germany Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 108:    Germany Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 109:    France Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 110:    France Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 111:    France Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 112:    France Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
Figure 113:    France Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 114:    France Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 115:    U.K. Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 116:    U.K. Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 117:    U.K. Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 118:    U.K. Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
Figure 119:    U.K. Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 120:    U.K. Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 121:    Italy Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 122:    Italy Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 123:    Italy Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 124:    Italy Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
Figure 125:    Italy Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 126:    U.S. Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 127:    Spain Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 128:    Spain Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 129:    Spain Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 130:    Spain Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
Figure 131:    Spain Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 132:    Spain Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 133:    Denmark Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 134:    Denmark Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 135:    Denmark Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 136:    Denmark Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
Figure 137:    Denmark Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 138:    Denmark Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 139:    Rest-of-Europe Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 140:    Rest-of-Europe Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 141:    Rest-of-Europe Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 142:    Rest-of-Europe Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
Figure 143:    Rest-of Europe Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 144:    Rest-of-Europe Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 145:    Asia-Pacific Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 146:    Asia-Pacific Hematologic Malignancies Testing Market (by Country), $Million, 2021-2032
Figure 147:    Asia-Pacific: Market Dynamics
Figure 148:    Asia-Pacific Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 149:    China Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 150:    China Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 151:    China Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 152:    China Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
Figure 153:    China Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 154:    China Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 155:    Japan Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 156:    Japan Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 157:    Japan Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 158:    Japan Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
Figure 159:    Japan Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 160:    Japan Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 161:    India Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 162:    India Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 163:    India Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 164:    India Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
Figure 165:    India Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 166:    India Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 167:    South Korea Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 168:    South Korea Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 169:    South Korea Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 170:    South Korea Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
Figure 171:    South Korea Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 172:    South Korea Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 173:    Australia Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 174:    Number of Death in Australia by Leukemia (2012-2017)
Figure 175:    Australia Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 176:    Australia Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 177:    Australia Hematologic Malignancies Testing Market (by Platform), Thousand Units, 2021, 2025, and 2032
Figure 178:    Australia Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 179:    Australia Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 180:    Singapore Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 181:    Singapore Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 182:    Singapore Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 183:    Singapore Hematologic Malignancies Testing Market (by Platform), Thousand Units, 2021, 2025, and 2032
Figure 184:    Singapore Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 185:    Singapore Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 186:    Rest-of-Asia-Pacific Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 187:    Rest-of-Asia-Pacific Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 188:    Rest-of-Asia-Pacific Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 189:    Rest-of-Asia-Pacific Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
Figure 190:    Rest-of-Asia-Pacific Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 191:    Rest-of-Asia-Pacific Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 192:    Latin America Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 193:    Latin America Hematologic Malignancies Testing Market (by Country), $Million, 2021-2032
Figure 194:    Latin America: Market Dynamics
Figure 195:    Latin America Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 196:    Brazil Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 197:    Brazil Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 198:    Brazil Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 199:    Brazil Hematologic Malignancies Testing Market (by Platform), Thousand Units, 2021, 2025, and 2032
Figure 200:    Brazil Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 201:    Brazil Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 202:    Mexico Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 203:    Mexico Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 204:    Mexico Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 205:    Mexico Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
Figure 206:    Mexico Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 207:    Mexico Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 208:    Rest-of-Latin America Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 209:    Rest-of-Latin America Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 210:    Rest-of-Latin America Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
Figure 211:    Rest-of-Latin America Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
Figure 212:    Rest-of-Latin America Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
Figure 213:    Rest-of-Latin America Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
Figure 214:    Rest-of-the-World Hematologic Malignancies Testing Market, $Million, 2021-2032
Figure 215:    Rest-of-the-World Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
Figure 216:    Total Number of Companies Profiled
Figure 217:    Abbott.: Overall Product Portfolio
Figure 218:    Abbott.: Overall Financials, $Million, 2019-2021
Figure 219:    Abbott.: Revenue (by Segment), $Million, 2019-2021
Figure 220:    Abbott.: Revenue (by Region), $Million, 2019-2021
Figure 221:    Abbott.: R&D Expenditure, $Million, 2019-2021
Figure 222:    ASURAGEN, INC.: Overall Product Portfolio
Figure 223:    Adaptive Biotechnologies: Overall Product Portfolio
Figure 224:    Adaptive Biotechnologies: Overall Financials, $Million, 2019-2021
Figure 225:    Adaptive Biotechnologies: Revenue (by Segment), $Million, 2019-2021
Figure 226:    Adaptive Biotechnologies: R&D Expenditure, $Million, 2019-2021
Figure 227:    ARUP Laboratories: Overall Product Portfolio
Figure 228:    Bio-Rad Laboratories, Inc.: Overall Product Portfolio
Figure 229:    Bio-Rad Laboratories, Inc.: Overall Financials, $Million, 2019-2021
Figure 230:    Bio-Rad Laboratories, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 231:    Bio-Rad Laboratories, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 232:    Bio-Rad Laboratories, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 233:    F. Hoffmann-La Roche Ltd: Overall Product Portfolio
Figure 234:    F. Hoffmann-La Roche Ltd: Overall Financials, $Million, 2019-2021
Figure 235:    F. Hoffmann-La Roche Ltd: Revenue (by Segment), $Million, 2019-2021
Figure 236:    F. Hoffmann-La Roche Ltd: Revenue (by Region), $Million, 2019-2021
Figure 237:    F. Hoffmann-La Roche Ltd: R&D Expenditure, $Million, 2019-2021
Figure 238:    Illumina, Inc.: Overall Product Portfolio
Figure 239:    Illumina, Inc.: Overall Financials, $Million, 2019-2021
Figure 240:    Illumina, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 241:    Illumina, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 242:    Illumina, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 243:    ICON plc: Overall Product Portfolio
Figure 244:    ICON plc: Overall Financials, $Million, 2019-2021
Figure 245:    ICON plc: Revenue (by Region), $Million, 2019-2021
Figure 246:    Invivoscribe, Inc.: Overall Product Portfolio
Figure 247:    Invitae Corporation.: Overall Product Portfolio
Figure 248:    Invitae Corporation.: Overall Financials, $Million, 2019-2021
Figure 249:    Invitae Corporation.: Revenue (by Segment), $Million, 2019-2021
Figure 250:    Invitae Corporation.: Revenue (by Region), $Million, 2019-2021
Figure 251:    Invitae Corporation.: R&D Expenditure, $Million, 2019-2021
Figure 252:    Laboratory Corporation of America Holdings: Overall Product Portfolio
Figure 253:    Laboratory Corporation of America Holdings: Overall Financials, $Million, 2019-2021
Figure 254:    Laboratory Corporation of America Holdings: Revenue (by Segment), $Million, 2019-2021
Figure 255:    Laboratory Corporation of America Holdings: Revenue (by Region), $Million, 2019-2021
Figure 256:    NeoGenomics Laboratories: Overall Product Portfolio
Figure 257:    NeoGenomics Laboratories: Overall Financials, $Million, 2019-2021
Figure 258:    NeoGenomics Laboratories: Revenue (by Segment), $Million, 2019-2021
Figure 259:    NeoGenomics Laboratories: R&D Expenditure, $Million, 2019-2021
Figure 260:    OHSU’s Knight Diagnostic Laboratories: Overall Product Portfolio
Figure 261:    Precipio: Overall Product Portfolio
Figure 262:    Precipio: Overall Financials, $Million, 2019-2021
Figure 263:    Precipio: Revenue (by Segment), $Million, 2019-2021
Figure 264:    QIAGEN N.V.: Overall Product Portfolio
Figure 265:    QIAGEN N.V.: Overall Financials, $Million, 2019-2021
Figure 266:    QIAGEN N.V.: Revenue (by Segment), $Million, 2019-2021
Figure 267:    QIAGEN N.V.: Revenue (by Region), $Million, 2019-2021
Figure 268:    QIAGEN N.V.: R&D Expenditure, $Million, 2019-2021
Figure 269:    Quest Diagnostics: Overall Product Portfolio
Figure 270:    Quest Diagnostics: Overall Financials, $Million, 2019-2021
Figure 271:    Quest Diagnostics: Revenue (by Segment), $Million, 2019-2021
Figure 272:    Sysmex Corporation: Overall Product Portfolio
Figure 273:    Sysmex Corporation: Overall Financials, $Million, 2018-2020
Figure 274:    Sysmex Corporation: Revenue (by Segment), $Million, 2018-2020
Figure 275:    Sysmex Corporation: Revenue (by Region), $Million, 2018-2020
Figure 276:    Sysmex Corporation: R&D Expenditure, $Million, 2018-2020

Market Report Coverage

Global Hematologic Malignancies Testing Market

Base Year

2021

Market Size in 2021

$2,606.5 Million

Forecast Period

2022-2032

Value Projection and Estimation by 2032

$11,680.1 Million

CAGR During Forecast Period

14.23%

Number of Tables

19

Number of Pages

278

Number of Figures

276

 

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

•    Abbott.
•    ASURAGEN, INC.
•    Adaptive Biotechnologies
•    ARUP Laboratories
•    Bio-Rad Laboratories, Inc.
•    F. Hoffmann-La Roche Ltd
•    Illumina, Inc.
•    ICON plc
•    Invivoscribe, Inc.
•    Invitae Corporation.
•    Laboratory Corporation of America Holdings
•    NeoGenomics Laboratories
•    OHSU’s Knight Diagnostic Laboratories
•    Precipio
•    QIAGEN N.V.
•    Quest Diagnostics
•    Sysmex Corporation

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: The product segment helps the reader understand the types of products, i.e., kits and services. These ecosystems are the primary focus of the study as these are the target of market players in terms of revenue generation. Moreover, the study provides the reader with a detailed understanding of the different diseases such as leukemia, lymphoma, multiple myeloma, myeloproliferative neoplasm, and myelodysplastic syndrome.

Growth/Marketing Strategy: The hematologic malignancies testing market has been dominated significantly by companies such as QIAGEN N.V., Abbott., Bio-Rad Laboratories, Inc., and F. Hoffmann-La Roche Ltd due to their expansive portfolio and strong regional presence across the world. Many companies such as Precipio, Sysmex Corporation, Illumina, Inc., ARUP Laboratories, and Adaptive Biotechnologies lie in the low growth and low market share segment. The low market share of these companies is primarily due to limited products with respect to the hematologic malignancies testing market in comparison to other segments of these companies. Also, the lack of synergistic activities with respect to the market is responsible for the low growth of these companies.

Competitive Strategy: Key players in the hematologic malignancies testing market analyzed and profiled in the study has involved the oncology application-based product manufacturers that provide hematologic malignancies testing kits and services. Moreover, a detailed competitive benchmarking of the players operating in the hematologic malignancies testing market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Industry & Technology Overview

Hematologic Malignancies Testing Market: Industry Overview

The global hematologic malignancies testing market is projected to reach $11,680.1 million by 2032, growing from $2,606.5 million in 2021, at a CAGR of 14.23% during the forecast period 2022-2032. The global market for hematologic malignancies testing has grown significantly, owing to the rising demand for numerous biomarker-based molecular diagnostics. The advancements have aided in enhancing the quality of life and decreasing treatment costs and time, driving the overall growth of the healthcare diagnostics market. Furthermore, the worldwide hematologic malignancies testing market is being driven by rising awareness and adoption of the precision diagnostic technique in both developed and developing countries.

Market Lifecycle Stage

Hematologic malignancies are a type of cancer that starts in blood-forming tissue, such as the bone marrow or immune system cells. With an enhanced genomic review of cancer and developments in molecular diagnostic technology, genetic characterization has become increasingly important in the clinical evaluation of practically every kind of hematologic malignancy. In economically developed countries, hematological malignancies (blood cancers) are the fifth most prevalent cancer kind. They're generally divided into three groups based on whether cancer starts in the blood (leukemia), lymph nodes (Hodgkin’s lymphoma and non-Hodgkin’s lymphoma), or bone (osteosarcomas and myelomas). The global hematologic malignancies testing market is undergoing a significant change about the advancements that have already taken place and are currently invading the market space. Additionally, with the emergence of advanced diagnostic technologies, there is immense potential for emerging submarkets such as the nucleic acid extraction market to continue fueling the overall hematologic malignancies testing market. Further, with highly opportunistic trends coming into play with the rapid incorporation of hematologic malignancies testing in the management of cancer in healthcare settings, there is immense potential for growth in this market.

Figure: Hematologic Malignancies Testing Market Snapshot

Global Hematologic Malignancies Testing Market

Source: BIS Research Analysis

Impact

•   The presence of major service providers of hematologic malignancies testing products has a significant impact on the market. For instance, In South Bend, Indiana, Laboratory Corporation of America Holdings opened a new diagnostics laboratory, allowing the company to expand service levels and products to patients and doctors in the area.
•   Companies such as F. Hoffmann-La Roche Ltd released the AVENIO Tumor Tissue CGP Kit, which complements Roche and Foundation Medicine's current CGP offering and enables laboratories to extend their oncology research in-house. In the end, a future version of the kit could result in more resources for clinicians to employ in cancer diagnosis and therapy. The presence of such products has a positive impact on market growth.

Impact of COVID-19

In the U.S. and around the world, cancer is the leading cause of death. Cancer testing is an important preventive measure that can lower the incidence and death of cancer. While cancer prevention and screening are important for individual and societal health, the cancer market is undergoing significant changes because of the COVID-19 epidemic. COVID-19-related disruptions have impacted nearly every area of cancer control and prevention infrastructure, which includes canceled cancer diagnostic tests, postponed elective surgeries, deconstructed therapy regimens, and unemployed healthcare providers. Patients, healthcare providers, and healthcare systems may all suffer because of the disruption in cancer screening tests.

Cancer screening is crucial for early cancer detection; however, COVID-19 has slowed the cancer screening infrastructure greatly. Many cancer organizations have championed the idea of suspending cancer screening services to patients to alter the provision of healthcare resources. Following the declaration of a national emergency in the U.S. on March 13, 2020, organizations such as the American Cancer Society advised people to put their cancer screening plans on hold until further notice during the COVID-19 outbreak. Cancer screening services have been severely disrupted because of this proposal, as well as other contextual circumstances (e.g., social exclusion measures).

Successful cancer screening is frequently achieved through synergistic collaborations among patients, healthcare providers, and health systems. Furthermore, because there is no information on the virus' origins and no effective vaccination or curative therapy, both patients and healthcare providers share the same unknowns and doubts about COVID-19. Health systems, whose financial prospects may be challenged, are also affected by this uncertainty. It is expected that, with the restrictions gradually being removed from several regions around the world, coupled with research activities resuming normalcy, the market will face a low impact on the annual revenue generation.

Market Segmentation

Segmentation 1: by Platform
•    Polymerase Chain Reaction (PCR)
•    Next-Generation Sequencing (NGS)
•    Fluorescence In-Situ Hybridization (FISH)
•    Flow Cytometry
•    Immunohistochemistry (IHC)
•    Other Platforms

The hematologic malignancies testing market (by platform) was dominated by the polymerase chain reaction (PCR) segment in 2021. This was due to an increasing number of PCR kits that providers offer to their end users.

Segmentation 2: by Disease
•    Leukemia
•    Lymphoma
•    Multiple Myeloma
•    Myeloproliferative Neoplasm
•    Myelodysplastic Syndrome

In 2021, leukemia disease dominated the hematologic malignancies testing market due to an increasing number of patients suffering from cancer. According to the data published by the World Health Organization, cancer is a leading cause of death, with nearly 10 million deaths reported in 2020.

Segmentation 3: by Product
•    Kits
•    Services

The hematologic malignancies testing market (by product) was dominated by the services segment in 2021. This growth was attributed to academic research and industry collaboration. Moreover, the technological advancement in RUO products is boosting the growth of the hematologic malignancies testing market.

Segmentation 4: by End User
•    Specialty Clinics and Hospitals
•    Diagnostic Laboratories 
•    Reference Laboratories
•    Research Institutions

In 2021, the hematologic malignancies testing market (by end user) was dominated by the specialty clinics, and hospitals segment as these clinics have all the necessary information and topic competence to perform disease diagnostic tests.

Segmentation 5: by Region
•    North America
•    Europe
•    Asia-Pacific
•    Latin America
•    Rest-of-the-World

North America generated the highest revenue of $1,491.7 million in 2021, which is attributed to the R&D advancements in the field of oncology testing and the presence of dominating players operating in the hematologic malignancies testing market.

Recent Developments in Hematologic Malignancies Testing Market

•    In August 2021, GRAIL, a healthcare business focused on life-saving early identification of various malignancies, was acquired by Illumina, Inc. The Galleri blood test developed by GRAIL diagnoses various malignancies before they become symptomatic. GRAIL's acquisition by Illumina has accelerated access to and acceptance of the life-saving test around the world.
•    In October 2021, F. Hoffmann-La Roche Ltd released the AVENIO Tumor Tissue CGP Kit, enabling laboratories to extend their oncology research in-house.
•    In January 2021, F. Hoffmann-La Roche Ltd partnered with Sysmex Corporation to evolve and provide hematology testing advances to laboratories around the world. The firms have renewed their long-standing distribution, sales, and services (DSS) agreement, allowing Roche to continue to distribute Sysmex hematology goods, including instruments and reagents.

Demand – Drivers and Limitations

Following are the demand drivers for the hematologic malignancies testing market:

•    Increasing Key Player Initiatives
•    Growing Funding in the Market for Hematologic Malignancies Testing

The market is expected to face some limitations too due to the following challenges:

•    Lack of Qualified Professionals
•    Issues Concerning the Analytical Validity of Cancer Genetic Testing

Analyst Thoughts

According to Nitish Kumar, Principal Analyst, BIS Research, "The hematologic malignancies testing market is an emerging segment comprising the overall diagnostics ecosystem. Moreover, the increasing prevalence of cancer and technological advancement in the field of cancer diagnostic are the significant factors driving the growth of the hematologic malignancies testing market."

You may also like

Published Year:2021

Molecular Diagnostics Market - A Global and Regional Analysis: Focus on Product, Testing Location, A

The global molecular diagnostics market is projected to reach $24,228.0 million by 2031 from...

Published Year:2021

Global Non-Invasive Liquid Biopsy Market: Focus on Offering, Sample, Application, Technology, End Us

The global non-invasive liquid biopsy market is projected to reach $9,470.3 million by 2031,...

Published Year:2020

Global Minimally Invasive Biopsy Technologies Market: Focus on Liquid Biopsy, Optical Biopsy, and Br

The minimally invasive biopsy technologies market industry analysis by BIS Research projects...

Global Hematologic Malignancies Testing Market

Focus on Hematologic Malignancies Testing Product and Application, Supply Chain Analysis, and Country Analysis - Analysis and Forecast, 2022-2032